NCT Number: NCT00046020
Study Evaluating Venlafaxine ER in Recurrent Depression
The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis for recurrent major depression
Exclusion criteria
- The patient has failed on an adequate trial of fluoxetine, venlafaxine or venlafaxine ER during the current episode of major depression or the patient is treatment-resistant
- Known hypersensitivity to venlafaxine or fluoxetine
- History or presence of clinically significant hepatic, cardiovascular or renal disease, or other serious medical disease, including history of seizure disorder
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term Randomized, Placebo-Controlled Maintenance Treatment Study in Patients Treated Initially With Venlafaxine ER
Important dates
- Study start
- 2000
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Sep 19, 2002
- Registry last updated
- Aug 14, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging
NCT03899168
Behavior, Behavioral Symptoms
View Trial DetailsIndividualized Functional Connectivity Targeting in aiTBS for Depression
NCT05680727
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsA Study of Psilocybin for Major Depressive Disorder (MDD)
NCT03866174
Behavior, Behavioral Symptoms
San Francisco, California, United States
View Trial DetailsTrial of Transcranial Photobiomodulation for Depression With PET and EEG Outcomes
NCT06934135
Anxiety Disorders, Behavior
Lima, Peru
View Trial Details